Maraviroc advisory committee
Executive Summary
FDA's Antiviral Drugs Advisory Committee will meet April 24 to review Pfizer's potential first-in-class HIV therapy maraviroc, according to a notice in the Federal Register Feb. 7. Pfizer will market the CCR5 antagonist candidate with Monogram's co-receptor tropism assay Trofile to identify patients who are most likely to respond to the drug class (1"The Pink Sheet" Dec. 18, 2006, p. 11). The meeting will be held at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md., beginning at 8 a.m...
You may also be interested in...
Pfizer Maraviroc Assay In HIV Is Model For Personalized Medicine, Firm Says
Pfizer is putting forward its partnership with assay developer Monogram Biosciences to advance its CCR5 antagonist candidate maraviroc as a model for targeted drug development
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.